LivaNova PLC (NASDAQ:LIVN) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lessened its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 3.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 401,372 shares of the company's stock after selling 12,360 shares during the period. Bank of New York Mellon Corp owned approximately 0.74% of LivaNova worth $18,588,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Central Pacific Bank Trust Division lifted its stake in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares during the period. Captrust Financial Advisors acquired a new stake in shares of LivaNova in the 3rd quarter worth $217,000. Sanctuary Advisors LLC acquired a new stake in shares of LivaNova in the third quarter valued at about $219,000. Edgestream Partners L.P. acquired a new stake in shares of LivaNova in the third quarter valued at about $244,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of LivaNova in the third quarter valued at about $292,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

LIVN has been the subject of several recent analyst reports. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 26th. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Barclays reduced their price objective on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research note on Friday, March 7th. The Goldman Sachs Group reduced their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Finally, Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $61.17.

Remove Ads

LivaNova Stock Performance

NASDAQ:LIVN opened at $39.06 on Wednesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average price of $46.47 and a two-hundred day moving average price of $49.25. LivaNova PLC has a twelve month low of $36.85 and a twelve month high of $64.47. The company has a market capitalization of $2.12 billion, a P/E ratio of 93.00 and a beta of 1.10.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.